In the present are certain Compounds, or pharmaceutically acceptable salts or prodrugs thereof. Also provided are Pharmaceutical compositions which comprise at least one Compound or pharmaceutically acceptable Salt or prodrug thereof, described in the present and one or more pharmaceutically acceptable vehicle.Methods are described for the treatment of patients suffering from certain diseases and disorders that respond to the inhibition of the activity of the KMO comprising administering to such patients an amount of at least one Compound or pharmaceutically acceptable Salt or prodrug thereof, d Written In this effective to reduce signs or symptoms of the disease or Disorder.These diseases include neurodegenerative Disorders such as Huntingtons disease.It also describes Methods of treatment include administering at least one Compound or pharmaceutically acceptable Salt or prodrug thereof, described here as a single Active agent or manage at least a compound or pharmaceutically acceptable Salt or prodrug my SMO described in this in combination with one or more other therapeutic agents.Also provided are methods to systematically Select compounds capable of inhibiting the activity of KMO.En la presente se proporcionan ciertos compuestos, o sales o profármacos farmacéuticamente aceptables de los mismos. También se proporcionan composiciones farmacéuticas que comprenden al menos un compuesto, o sal o profármaco farmacéuticamente aceptable del mismo, descrito en la presente y uno o más vehículos farmacéuticamente aceptables. Se describen métodos de tratamiento de pacientes que padecen ciertas enfermedades y trastornos que responden a la inhibición de la actividad de la KMO que comprenden administrar a dichos pacientes una cantidad de al menos un compuesto, o sal o profármaco farmacéuticamente aceptable del mismo, descrita en la presente eficaz para reducir los signos o síntomas de la enfermedad o trastorno. Estas enfermedades incluyen patologías neurodegenerativas tales c
